Results 1 to 10 of about 10,049 (121)

Toward Systems Biomarkers of Response to Immune Checkpoint Blockers [PDF]

Frontiers in Oncology, 2020
Immunotherapy with checkpoint blockers (ICBs), aimed at unleashing the immune response toward tumor cells, has shown a great improvement in overall patient survival compared to standard therapy, but only in a subset of patients.
Óscar Lapuente-Santana, Federica Eduati, Federica Eduati   +2 more
doaj   +5 more sources

Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers [PDF]

Exploration of Targeted Anti-tumor Therapy, 2022
In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant.
Shiu Ying Tsao
doaj   +4 more sources

Immune checkpoint blockers and ovarian cancer [PDF]

Indian Journal of Medical and Paediatric Oncology, 2017
Although the idea, called “cancer immunotherapy,” is very appealing and has previously been shown to work in several mouse models of cancer, it has in general been very difficult to translate cancer immunotherapy approaches to humans.
Chinmoy K Bose
doaj   +4 more sources

Trial watch: Immune checkpoint blockers for cancer therapy [PDF]

OncoImmunology, 2017
Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications.
Claire Vanpouille-Box, Claire Lhuillier, Lucillia Bezu, Fernando Aranda, Takahiro Yamazaki, Oliver Kepp, Jitka Fucikova, Radek Spisek, Sandra Demaria, Silvia C. Formenti, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi   +12 more
doaj   +5 more sources

Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers [PDF]

Journal for ImmunoTherapy of Cancer
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many malignant tumors. However, ICI-induced hyper-immune activation causes cardiotoxicity.
Ping Li, Zhen Qin, Yang Lu, Jiamin Gao, Zhenwei Wang, Ge Zhang, Han Yang, Yachen Hou, Dashuai Wang, Pengchong Du, Yunzhe Wang, Quanzhou Chen, Zhaowei Sun, Jinying Zhang, Junnan Tang   +14 more
doaj   +4 more sources

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects [PDF]

Journal for ImmunoTherapy of Cancer, 2020
Background Oxazaphosphorines (cyclophosphamide (CPA), ifosfamide (IFO)) are major alkylating agents of polychemotherapy protocols but limiting their toxicity and increasing their efficacy could be of major interest.
Mélanie Desbois, Nathalie Chaput, Julia Delahousse, Charles Skarbek, Jean-Luc Perfettini, Angelo Paci   +5 more
doaj   +5 more sources

Biomarkers for immune checkpoint blockers [PDF]

HemaSphere, 2018
Kirsty Wienand, Margaret A. Shipp
doaj   +3 more sources

Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy [PDF]

Frontiers in Oncology, 2022
Mazdak Ganjalikhani-Hakemi, Ling Xu, Andrey A. Zamyatnin, Andrey A. Zamyatnin, Andrey A. Zamyatnin, Andrey A. Zamyatnin, Alexandr V. Bazhin, Alexandr V. Bazhin   +7 more
doaj   +5 more sources

Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients [PDF]

OncoImmunology, 2019
CTLA4 blockers have limited activity in patients with chemorefractory lung cancer. Recent clinical data demonstrate that radiation therapy combined with CTLA4 blockers enables disease control in a sizeable fraction of these patients, correlating with ...
Eric C. Ko, Lorenzo Galluzzi
doaj   +5 more sources

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance [PDF]

Frontiers in Cell and Developmental Biology, 2020
In recent years, as our understanding of tumor immunology is continuously improved, immunotherapy has come to the center stage of cancer therapy and is deemed as the most promising approach for cancer control.
Qian Huang, Yanna Lei, Xiaoying Li, Fukun Guo, Ming Liu   +4 more
doaj   +3 more sources